Omeros announces journal of clinical oncology publication detailing pivotal trial results for narsoplimab in hsct-tma

Seattle--(business wire)--omeros corporation (nasdaq: omer) today announced the online publication of a manuscript detailing the results of its pivotal study assessing efficacy and safety of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma), an often-lethal complication of stem-cell transplantation for which there is no approved treatment. the manuscript – narsoplimab, a mannan-binding lectin-associated serine protease-2 inhibit
OMER Ratings Summary
OMER Quant Ranking